A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
AbstractBasal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients wit...
Source: Diabetes Therapy - April 13, 2018 Category: Endocrinology Source Type: research
Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis
ConclusionRapid-acting insulin analogs appear generally safe and effective in these special populations; however, additional trials would be helpful.FundingNovo Nordisk A/S. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 5, 2018 Category: Endocrinology Source Type: research
Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial
ConclusionLM50 achieved better overall glycemic control than LM25 as a starter insulin in Chinese patients, which may be due to greater improvement in PPG levels.Trial RegistrationClinicaltrials.gov identification number: NCT01773473.FundingEli Lilly and Company, Shanghai, China. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 24, 2018 Category: Endocrinology Source Type: research
Effects of Intranasal Insulin on Endogenous Glucose Production in Insulin Resistant Men
The effects of intranasal insulin on the regulation of endogenous glucose production (EGP) in individuals with insulin resistance were assessed in a single‐blind, crossover study. Overweight or obese insulin resistant men (n=7; BMI 35.4 +/‐ 4.4 kg/m2; HOMA‐IR 5.6+/‐1.6) received intranasal spray of either 40 IU insulin lispro or placebo in 2 randomized visits. Acute systemic spillover of intranasal insulin into the circulation was matched with a 30‐min intravenous infusion of insulin lispro in the nasal placebo arm. EGP was assessed under conditions of a pancreatic clamp with a primed, constant infusion of glucos...
Source: Diabetes, Obesity and Metabolism - March 14, 2018 Category: Endocrinology Authors: Changting Xiao, Satya Dash, Priska Stahel, Gary F. Lewis Tags: BRIEF REPORT Source Type: research
Effects of Insulin Lispro Mix 25 and Insulin Lispro Mix 50 on Postprandial Glucose Excursion in Patients with Type 2 Diabetes: A Prospective, Open-Label, Randomized Clinical Trial
ConclusionsLM50 may provide better glycemic excursion control after breakfast and dinner than LM25 in T2DM patients.Trial Registrationhttp://www.chictr.org.cn # ChiCTR-TTRCC-12002516.FundingLilly Suzhou Pharmaceutical Co., Ltd. (Shanghai Branch, China) and National Key Program of Clinical Science of China (WBYZ 2011-873). (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 8, 2018 Category: Endocrinology Source Type: research
Transient Neonatal Diabetes Mellitus in a Very Preterm Infant due to ABCC8 Mutation
We report the case of a preterm infant with TNDM due to an ABCC8 mutation identified by next-generation sequencing. The pancreatic adenosine triphosphate (ATP)-sensitive K+ (K-ATP) channel is a key regulator of insulin secretion. Gain-of-function mutations in the genes encoding the Kir6.2 (KCNJ11) and SUR1 (ABCC8) subunits of the channel cause neonatal diabetes. The patient was successfully managed with insulin lispro at a 1:100 dilution, drawn up in an insulin pen injector with a 4-mm needle. The insulin lispro dilution allowed administration of the exact insulin doses, obtaining a good glycemic control and minimizing the...
Source: American Journal of Perinatology Reports - March 7, 2018 Category: Perinatology & Neonatology Authors: Piccini, Barbara Coviello, Caterina Drovandi, Livia Rosangela, Artuso Monzali, Francesca Casalini, Emilio Giglio, Sabrina Toni, Sonia Dani, Carlo Tags: Case Report Source Type: research
New Human Insulin Analog Approved
The FDA hasapproved another formulation of insulin lispro —a type of rapid-acting human insulin analog—to improve glycemic control in adults and children aged 3 years or older with type 1 diabetes and in adults with type 2 diabetes. Marketed as Admelog, the product is a follow-on drug approved through an abbreviated pathway that relied in part on its s imilarity to Humalog, an insulin lispro approved in1996. (Source: JAMA)
Source: JAMA - February 6, 2018 Category: General Medicine Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology&Therapeutics,Volume 20, Issue 2, Page 160-170, February 2018. (Source: Diabetes Technology)
Source: Diabetes Technology - February 1, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology&Therapeutics,Volume 20, Issue 2, Page 160-170, February 2018. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - February 1, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology&Therapeutics,Volume 20, Issue 2, Page 160-170, February 2018. (Source: Diabetes Technology)
Source: Diabetes Technology - February 1, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology&Therapeutics,Volume 20, Issue 2, Page 160-170, February 2018. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - February 1, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology&Therapeutics,Volume 20, Issue 2, Page 160-170, February 2018. (Source: Diabetes Technology)
Source: Diabetes Technology - February 1, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology&Therapeutics,Volume 20, Issue 2, Page 160-170, February 2018. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - February 1, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology& Therapeutics Feb 2018, Vol. 20, No. 2: 160-170. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - January 23, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
Diabetes Technology& Therapeutics Feb 2018, Vol. 20, No. 2: 160-170. (Source: Diabetes Technology)
Source: Diabetes Technology - January 23, 2018 Category: Endocrinology Authors: Philip Home Karl-Michael Derwahl Monika Ziemen Karin Wernicke-Panten Suzanne Pierre Yvonne Kirchhein Satish K. Garg Source Type: research
